Option chain shows key data for Hoth Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Hoth Therapeutics.

Hoth Therapeutics (NASDAQ:HOTH) Stock, Option Chain

Hoth Therapeutics

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

AMPG

AREB

BHAT

BWMN

CALM

DATS

DRIO

EONR

GRFX

HOTH

JBDI

LAES

RGTI

RIME

SANA

SLDB

SVMH

XTIA

Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket

Konskie,,Poland,-,December,03,,2024:,Rpm,International,Company,Logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMST

CTAS

GETY

LFWD

SLRN

SSTK

Nasdaq Down 1.5%; RPM Posts Upbeat Results

biotech shutter

Biotech

Health Care

Movers

General

Hoth Therapeutics&#39; HT-001 shows promising interim Phase 2a trial results, improving skin toxicities in cancer patients without treatment-related adverse effects.

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Hoth Therapeutics Inc

Press Releases

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Dare Bioscience

Durect

Gelteq

Impact BioMedical

IGC Pharma

Jaguar Health

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Talphera

Traws Pharma

TherapeuticsMD

D. Boral Capital

HC Wainwright & Co.

Benchmark

EF Hutton

Comments

Hoth Therapeutics

Hoth Therapeutics (HOTH) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga